Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery

Zhang, Chan; Li, Zhao; Dong, Yuefeng; Zhang, Xiaoyan; Lin, Ji; Chen, Zhang

doi:10.1016/j.ejpb.2010.05.005

Cited by 105 publications

(55 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DOX/P(HB-HO) NPs (223.2 ± 5.1 nm) and DOX/FA-PEG-P(HB-HO) NPs (241.6 ± 9.3 nm) for cancer treatment applications were prepared by the W 1 /O/W 2 solvent extraction/ evaporation method, as described previously (Zhang et al, 2010). Briefly, P(HB-HO) [or FA-PEG-P(HB-HO)] was dissolved in chloroform containing emulsifiers.…”

Section: Chemicals and Reagentsmentioning

confidence: 99%

See 1 more Smart Citation

Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay

Zhang

Dong³

et al. 2015

Pharmaceutical Biology

Self Cite

View full text Add to dashboard Cite

Results: The t 1/2 values of DOX/P(HB-HO) NPs and DOX/FA-PEG-P(HB-HO) NPs were 2.7-and 3.5-times higher than that of free DOX. No significant difference (p40.05) was found in C max between the NPs and free DOX. The T max values of the two NPs were prolonged from 0.25 to 1 h. The AUC 0-t values were 1.55-and 3.05-folds higher than that of free DOX, and MRT increased to 15.99 h for DOX/P(HB-HO) NPs and 25.14 h for DOX/FA-PEG-P(HB-HO) NPs. For DOX/FA-PEG-P(HB-HO) NPs, the DOX content in the tumors were 10.81-and 3.33-times higher than those for free DOX and DOX/P(HB-HO) NPs at 48 h, respectively. Discussion and conclusions: DOX/FA-PEG-P(HB-HO) NPs displayed reduced cardiac toxicity and improved bioavailability. Moreover, the NPs exhibited a significant extent of DOX accumulation in the tumors, thus suggesting that folate-targeted NPs could effectively transport into HeLa tumors with satisfying targeting.

show abstract

Section: Chemicals and Reagentsmentioning

confidence: 99%

“…And P(HB-HO) is used as a drug carrier because of its biodegradation (Guo et al, 2009) and biocompatibility (Dong et al, 2008). P(HB-HO) microspheres (Zhang et al, 2014) and folate-targeted NPs (Zhang et al, 2010) were prepared in our previous study.…”

Section: Introductionmentioning

confidence: 99%

Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay

Zhang

Dong³

et al. 2015

Pharmaceutical Biology

Self Cite

View full text Add to dashboard Cite

show abstract

“…19,39 Human cervical carcinoma cells devoid of folate receptor are incapable of cellular uptake of folateconjugated NPs. 40 Similarly, enhanced antiproliferative potential of epirubicin going from folate receptor (−) to folate receptor (++) cells was also observed. 41 The uptake of folic acid-conjugated doxorubicin by HeLa cells has also been reported.…”

Section: Targeting Tumor Cellsmentioning

confidence: 85%

“…41 The uptake of folic acid-conjugated doxorubicin by HeLa cells has also been reported. 40 The anticancer activity of transferring-conjugated solid-lipid NPs of curcumin on the MCF-7 cell line is also evident. 42 Several such studies suggested the potential of targeted therapeutic nanoparticles (TNPs) as effective anticancer drug-delivery systems.…”

Section: Targeting Tumor Cellsmentioning

confidence: 93%

“…42 Several such studies suggested the potential of targeted therapeutic nanoparticles (TNPs) as effective anticancer drug-delivery systems. 2,22,25,40,43 In an in vivo animal study, targeted TNP-delivered paclitaxel was mainly located in tumor cells, while nontargeted TNP-delivered paclitaxel was detected at intercellular level. 44 …”

Section: Targeting Tumor Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Nanotechnology-based approaches in anticancer research

Jabir¹,

Tabrez²,

Ashraf³

et al. 2012

IJN

145

View full text Add to dashboard Cite

Cancer is a highly complex disease to understand, because it entails multiple cellular physiological systems. The most common cancer treatments are restricted to chemotherapy, radiation and surgery. Moreover, the early recognition and treatment of cancer remains a technological bottleneck. There is an urgent need to develop new and innovative technologies that could help to delineate tumor margins, identify residual tumor cells and micrometastases, and determine whether a tumor has been completely removed or not. Nanotechnology has witnessed significant progress in the past few decades, and its effect is widespread nowadays in every field. Nanoparticles can be modified in numerous ways to prolong circulation, enhance drug localization, increase drug efficacy, and potentially decrease chances of multidrug resistance by the use of nanotechnology. Recently, research in the field of cancer nanotechnology has made remarkable advances. The present review summarizes the application of various nanotechnology-based approaches towards the diagnostics and therapeutics of cancer.

show abstract